Brief: Poxel Announces Completion Of Patient Enrollment For Times 2 Trial In Phase 3 Registration Program For Imeglimin In Japan

Poxel SA

08/10/2018 07:13

Oct 8 (Reuters) - Poxel SA  POXEL.PA :
    * ANNOUNCES COMPLETION OF PATIENT ENROLLMENT FOR TIMES 2
TRIAL IN
PHASE 3 REGISTRATION PROGRAM FOR IMEGLIMIN, AN INVESTIGATIONAL
THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN
    * PHASE 3 TIMES 1, TIMES 2 AND TIMES 3 TRIALS FOR IMEGLIMIN
ARE
NOW FULLY ENROLLED WITH OVER 1,100 PATIENTS
    * PHASE 3 TIMES DATA RESULTS ARE ON TRACK FOR 2019
    * JAPANESE NEW DRUG APPLICATION SUBMISSION FOR IMEGLIMIN
TARGETED
IN 2020

Source text for Eikon:  ID:nBw3vWLh3a 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))